Price movement over the last 24 hours
ADMA Biologics Inc vs ProShares Bitcoin ETF — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while ProShares Bitcoin ETF trades at $8.38. The key difference: ADMA Biologics Inc is trading nearer its 52-week high, ProShares Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| ADMA | BITO | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Crypto-linked |
52-Week High | $20.38 | $23.05 |
52-Week Low | $7.60 | $7.98 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
BITO trades at $8.64, up 3.6% over 24 hours amid a mixed technical picture with a bullish overall signal but bearish moving averages. Recent dividend distributions of $0.01-$0.02 per share provide modest income, though financial ratios like P/E and P/S are unavailable. News sentiment reflects caution as the fund faces scrutiny over performance gaps versus Bitcoin and fee structures.
Outlook remains clouded by volatile crypto markets and investor skepticism; risks include fee drag and regulatory uncertainty. Analysts highlight distribution cuts and correlation shifts, suggesting limited near-term catalysts. Investors should weigh income against potential capital erosion in a challenging environment.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →BITO offers exposure to Bitcoin returns primarily through Bitcoin futures contracts. It provides a regulated way for investors to trade Bitcoin performance within a traditional brokerage account without direct ownership.
Read more on BITO →